Regulatory Update
|
23 May 2013
0 Likes 
The European Commission has released the names of the first members to sit on the panel of experts it established in 2012 to provide advice to Member States on ways to contain healthcare
Read More...
Regulatory Update
|
20 May 2013
0 Likes
The China Food and Drug Administration (CFDA) has issued a notice setting deadlines for implementing electronic monitoring for imported essential drugs. Imported drugs in domestic packaging must
Read More...
Regulatory Update
|
20 May 2013
0 Likes
International regulatory authorities are involved in discussions regarding the possible creation of a new International Coalition for Drug Regulatory Agencies (ICDRA), the Brazilian regulatory agency
Read More...
Regulatory Update
|
17 May 2013
0 Likes
The European Commission’s three Scientific Committees have been requested to provide a joint scientific opinion on the relationship of Synthetic Biology (SB) to genetic modification of organisms, its
Read More...
Regulatory Update
|
15 May 2013
-1 Likes
China’s Food and Drug Administration (CFDA) last week issued instructions to Chinese provinces regarding the requirements for certifying active pharmaceutical ingredient manufacturers for the right to
Read More...
Regulatory Update
|
14 May 2013
1 Likes
Australia's Therapeutic Goods Administration (TGA) has opened a consultation to seek views from interested parties on the value, feasibility, design and impacts of a proposed new-to-market risk
Read More...
Regulatory Update
|
13 May 2013
0 Likes
The Committee on Social Security and Family of Brazil’s House of Representatives held a hearing on 9 May 2013 on the scope of regulatory authority of Brazil’s National Health Surveillance Agency
Read More...
Latest News
Regulatory Update
|
6 May 2013
0 Likes
Australia’s Therapeutic Goods Administration (TGA) has opened a consultation on proposed amendments to the new regulatory framework for in vitro diagnostic devices (IVDs) that covers both commercially
Read More...
Latest News
Regulatory Update
|
2 May 2013
0 Likes
The UK’s cost containment agency, the National Institute for Health and Care Excellence (NICE), will soon begin to directly assist the National Health Service (NHS) with the use of innovative new
Read More...
Regulatory Update
|
25 April 2013
0 Likes
The UK’s cost containment agency, the National Institute for Health and Care Excellence (NICE), has given its approval in final guidance for the reimbursement of Novartis’ Xolair (omalizumab) for the
Read More...